Johnson & Johnson (JNJ) Gains Spot on Wolfe Favorites amid Growth Outlook

Johnson & Johnson (NYSE:JNJ) is included among the Dividend Kings and Aristocrats List: 32 Biggest Stocks.

Johnson & Johnson (NYSE:JNJ) was included in Wolfe Research’s favorite stocks list, according to a CNBC report published on March 16. The company currently offers a dividend yield of around 2.15%, and last increased its payout in May 2025.

The report mentioned that earlier this year, Johnson & Johnson reached an agreement with the Trump administration to lower drug prices for consumers in exchange for tariff exemptions. As part of that effort, it recently launched a website that allows patients to buy certain products directly, including those without insurance or those choosing to pay out of pocket.

The company continues to expand its pipeline, with treatments in development across areas like cancer, Crohn’s disease, and depression. Earlier in March, it shared early results from a Phase 1 trial for a bladder cancer treatment, reporting “complete and durable responses” in patients. Johnson & Johnson also issued solid sales and profit guidance for 2026 earlier this year. The company is set to report its first-quarter results on April 14.

Johnson & Johnson (NYSE:JNJ)  operates as a diversified healthcare company with three main segments: Innovative Medicine, MedTech, and Consumer Health. Its portfolio spans pharmaceuticals, medical devices, and widely used consumer health products.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Dividend Stocks to Buy for Steady Income and 14 Under-the-Radar High Dividend Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.